awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q39227773-056FABD5-850A-45B5-AB80-DA9CBBCF91F3
Q39227773-056FABD5-850A-45B5-AB80-DA9CBBCF91F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39227773-056FABD5-850A-45B5-AB80-DA9CBBCF91F3
Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
P2860
Q39227773-056FABD5-850A-45B5-AB80-DA9CBBCF91F3
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39227773-056FABD5-850A-45B5-AB80-DA9CBBCF91F3
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9444a9199b8ee9418de3e020860b9ec179a5c4ce
P2860
Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.